On Thursday,
Algernon Pharmaceuticals Inc. (CSE: AGN, OTCQB: AGNPF, Forum) provided investors with additional information on its business plans for 2021, including establishing one to two new clinical research programs in calendar Q1, with plans to start clinical trials before the end of the year, along with increasing the enrollment rate of its IPF and chronic cough study, and projecting that the final data set for the Phase 2b part of its Phase 2b/3 clinical trial from its NP-120 (Ifenprodil) COVID-19 clinical study will be available by the end of February 2021.
For the full news release, click
here.
The Vancouver, BC-based clinical stage pharmaceutical development and drug repurposing Company had
a significant 2020 for furthering its operations, including its NP-120 Ifenprodil Idiopathic Pulmonary Fibrosis (IPF) & Chronic Cough Clinical Research Program and Ifenprodil COVID-19 Clinical Research Program.
FULL DISCLOSURE: Algernon Pharmaceuticals Inc. is a client of Stockhouse Publishing.